Share Name Share Symbol Market Type Share ISIN Share Description
E-Therapeutics LSE:ETX London Ordinary Share GB00B2823H99 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 12.125p 12.00p 12.25p 12.125p 12.125p 12.125p 230,830 07:53:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -16.2 -4.9 - 32.54

E-Therapeutics Share Discussion Threads

Showing 201 to 222 of 225 messages
Chat Pages: 9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
16/6/2017
11:13
Someone / people seem to be loading up here, insider trading ?
eastbourne1982
14/6/2017
23:07
whats going on here - looks like a concert party buying in free stock charts from uk.advfn.com
luckymouse
14/6/2017
16:22
Back to 40 highs
letmepass
02/6/2017
18:24
As to why Richard Griffiths picked up c 54m ( from Aviva I guess) , and Lombard bought an extra 5m? Not sure, but it certainly woke things up, alongside the directors' buy.
hutch_pod
02/6/2017
16:22
lots happening today any info as to why?
dynoport
09/1/2017
07:11
Well, the new CEO seems impressive.
hutch_pod
20/9/2016
07:10
Founder leaving cannot be good :(
dynoport
26/5/2016
11:48
timbo, a good point. There was not a resolution on directors' remuneration. I guess it is not required for AIM companies.
gnnmartin
26/5/2016
09:46
Hi gnnmartin, thank you for the helpful writeup. Interesting to see the Searchbolt acquisition as defensive, and especially if the focus is now on the platform and partnering deals. Cheers HP
hutch_pod
25/5/2016
21:51
Nigel, could it be anything to do with Malcolm's ridiculously large remuneration? He has to be the best paid CEO (by a mile) for any sub £100m life sciences company on AIM. Was it a similar voting pattern for the resolutions concerning the remuneration report and remuneration policy?
timbo003
25/5/2016
20:28
I went to the AGM today. Nothing new to report. I went to ask for more information about the proposal to buy back Searchbolt that TW was so scathing about. Iain Ross, non-exec chairman appointed January this year, told me that it was his guidance that triggered the action. Searchbolt had not been commercially successful and had some creditors that had potential spoiling power should ETX be successful in signing up a major pharmaceutical partner. Iain thought the possibility a patent troll like action from 3rd parties would be sufficiently off-putting to a major pharma, and it was worth (effectively) buying out the creditors. I accept the explanation, though I don't know enough about the industry to make any informed judgement. I assume the concern is a consequence of the change of focus mentioned in the annual report: "Since originally identifying our first lead development compounds, substantial investment has enabled us to accelerate the development and expand the Company’s discovery capabilities and infrastructure. The platform is now the core focus for the business as it provides fast and accurate data enabling the identification of highly potent novel compounds which have the potential to be ‘game changers’ in established multiple, billion dollar markets. One oddity came out of the meeting, possibly of no significance. The 4th motion was to re-elect Malcolm Young as director, and 3 proxy voters holding 47.3m votes between them abstained. I asked if there was any background to this, but was told no. Usually a deliberate abstention (as opposed to simply not bothering to vote) expresses some mild dissatisfaction or concern. With that number of votes being cast, one of the 3 abstainers was either Woodford or Aviva. Malcolm seems pretty central to the company strategy.
gnnmartin
20/5/2016
13:06
Cheers gooner108, bit of a punt on this one but could be big optionality
postmanpat11
11/5/2016
18:50
Tom W.[Shareprophets] has a low opinion of this share. Worth checking.
geoff80
22/3/2016
23:11
Agree. Looks like decent potential.
hutch_pod
22/3/2016
22:14
Thanks for the link ProactiveST. Good credible interview, very confident CEO with exciting propects for the future of the company.
jesusm
22/3/2016
15:23
Video interview with Malcolm Young http://tinyurl.com/h3uye57 e-Therapeutics plc (LON:ETX) is targeting partners to accelerate the development of its drug discovery engine, it told investors on Tuesday. Malcolm Young, chief executive, tells Proactive that “making alliances with much larger companies is absolutely our foreground so that’s where we need to go, that’s where our frontier is, that’s where we need to make the advances.” He adds “commercialisation as a focus in the company has really grown in significance in this last year,” and that the firm is looking for partnerships as a way to recognise the commercial value of both late stage and early stage products.
proactivest
24/2/2016
12:08
someone knows something, we'll know tomorrow!
dynoport
24/2/2016
10:22
down 21pc- any idea why?- this one has got Woodford invested and a string of well known managers!
ali47fish
15/2/2016
14:33
Not an investor here but have seen a few presentations at Mayfair. They looked interesting at that time. Today's RNS seems weird to me. It seemed to be presented as good news when it is probably anything but. A massive drop first thing and any bottom feeders would have done well. I can't see given the wooliness of the RNS any great upside on this so I confess I am slightly bemused by the share price partial recovery since the opening.
mach100
15/2/2016
14:19
Video interview with CEO Young http://tinyurl.com/h7g4rnn E-Therapeutics (LON:ETX) chief executive Malcolm Young tells Proactive that the firm has hit the “sweet spot” on the drug candidate ETS6103 following its latest test results. The Phase IIb study, which was a larger study at a lower dose showed the drug was a little bit off the efficacy of its rival amitriptyline, but was still effective. But the firm has previously completed a Phase IIa study on ETS6103, which was carried out on a small number of patients at a higher dose, showing the drug had the same efficacy as its closest rival. Young says that the drug has a “cleaner profile” than amitriptyline, and adds that “across the two studies, we are pleased.”
proactivest
15/2/2016
07:48
Yes. Disappointing results.ETS6103 confirmed as effective in treating second line depressive conditions but not as effective as tricyclics (which is what was hoped).Tricyclics have more side effects and so they hold onto this as giving ETS6103 some value; but overall the results are disappointing IMO.
longshanks
15/2/2016
07:30
Eh? can anyone decipher this? http://uk.advfn.com/stock-market/london/e-therapeutics-ETX/share-news/e-Therapeutics-plc-Top-line-Phase-IIb-results-upda/70373914
dynoport
Chat Pages: 9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170723 18:52:19